Protagonist Therapeutics, Inc. (PTGX)
136.24
+0.34
(+0.25%)
USD |
NASDAQ |
Nov 10, 16:00
136.24
0.00 (0.00%)
After-Hours: 17:41
Protagonist Therapeutics Gross Profit Margin (Quarterly) : 99.45% for Sept. 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 99.45% |
| June 30, 2026 | 99.81% |
| March 31, 2026 | 99.28% |
| December 31, 2025 | 94.94% |
| September 30, 2025 | 92.34% |
| June 30, 2025 | 94.52% |
| March 31, 2025 | 99.16% |
| December 31, 2024 | 99.65% |
| September 30, 2024 | 86.16% |
| June 30, 2024 | 78.59% |
| March 31, 2024 | 99.68% |
| December 31, 2023 | 98.61% |
| September 30, 2023 | |
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | |
| September 30, 2022 | |
| June 30, 2022 | 1.86% |
| March 31, 2022 | 96.76% |
| Date | Value |
|---|---|
| December 31, 2021 | 90.50% |
| September 30, 2021 | 0.00% |
| June 30, 2021 | 0.00% |
| March 31, 2021 | 0.00% |
| December 31, 2020 | 0.00% |
| September 30, 2020 | 0.00% |
| June 30, 2020 | 0.00% |
| March 31, 2020 | 0.00% |
| December 31, 2019 | 0.00% |
| September 30, 2019 | 0.00% |
| June 30, 2019 | 0.00% |
| March 31, 2019 | 0.00% |
| December 31, 2018 | 0.00% |
| September 30, 2018 | 0.00% |
| June 30, 2018 | 0.00% |
| March 31, 2018 | 0.00% |
| December 31, 2017 | 0.00% |
| September 30, 2017 | 0.00% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Johnson & Johnson | 68.11% |
| AbbVie, Inc. | 75.33% |
| BioMarin Pharmaceutical, Inc. | 70.24% |
| Gilead Sciences, Inc. | 81.09% |
| Nektar Therapeutics | 98.46% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | 44.54% |
| Return on Assets | 41.73% |
| Return on Invested Capital | 43.98% |
| Profit Margin (Quarterly) | 80.18% |
| Operating Margin (Quarterly) | 79.56% |
| Return on Net Operating Assets | 381.5% |